Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Antipsychotics frequently cause obesity and related metabolic disorders that current psychopharmacological/endocrinological theories do not explain consistently. An integrative/alternative theory implies metabolic alterations happening at the cellular level. Many observations in vitro and in vivo, and pivotal observations in humans, point towards chemical properties of antipsychotics, independent of receptor binding characteristics. Being amphiphilic weak bases, antipsychotics can disrupt lysosomal function, affecting cholesterol trafficking; moreover, by chemical mimicry, antipsychotics can inhibit cholesterol biosynthesis. These two molecular adverse effects may trigger a cascade of transcriptional and biochemical events, ultimately reducing available cholesterol while increasing cholesterol precursors and fatty acids. The macroscopic manifestation of these molecular alterations includes decreased high-density lipoprotein and increased very low-density lipoprotein and triglycerides that may translate into obesity and related metabolic disorders.

Original languageEnglish
JournalTrends in Endocrinology and Metabolism
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Lipid Metabolism
Antipsychotic Agents
Cholesterol
Obesity
HDL Lipoproteins
Fatty Acids

Keywords

  • antipsychotic drugs
  • cholesterol
  • lysosomal trapping
  • metabolism
  • SREBP
  • weight

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{a5408015841048df8522bcae72d78d7f,
title = "Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking",
abstract = "Antipsychotics frequently cause obesity and related metabolic disorders that current psychopharmacological/endocrinological theories do not explain consistently. An integrative/alternative theory implies metabolic alterations happening at the cellular level. Many observations in vitro and in vivo, and pivotal observations in humans, point towards chemical properties of antipsychotics, independent of receptor binding characteristics. Being amphiphilic weak bases, antipsychotics can disrupt lysosomal function, affecting cholesterol trafficking; moreover, by chemical mimicry, antipsychotics can inhibit cholesterol biosynthesis. These two molecular adverse effects may trigger a cascade of transcriptional and biochemical events, ultimately reducing available cholesterol while increasing cholesterol precursors and fatty acids. The macroscopic manifestation of these molecular alterations includes decreased high-density lipoprotein and increased very low-density lipoprotein and triglycerides that may translate into obesity and related metabolic disorders.",
keywords = "antipsychotic drugs, cholesterol, lysosomal trapping, metabolism, SREBP, weight",
author = "Chiara Vantaggiato and Elena Panzeri and Andrea Citterio and Genny Orso and Marco Pozzi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.tem.2019.01.003",
language = "English",
journal = "Trends in Endocrinology and Metabolism",
issn = "1043-2760",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking

AU - Vantaggiato, Chiara

AU - Panzeri, Elena

AU - Citterio, Andrea

AU - Orso, Genny

AU - Pozzi, Marco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Antipsychotics frequently cause obesity and related metabolic disorders that current psychopharmacological/endocrinological theories do not explain consistently. An integrative/alternative theory implies metabolic alterations happening at the cellular level. Many observations in vitro and in vivo, and pivotal observations in humans, point towards chemical properties of antipsychotics, independent of receptor binding characteristics. Being amphiphilic weak bases, antipsychotics can disrupt lysosomal function, affecting cholesterol trafficking; moreover, by chemical mimicry, antipsychotics can inhibit cholesterol biosynthesis. These two molecular adverse effects may trigger a cascade of transcriptional and biochemical events, ultimately reducing available cholesterol while increasing cholesterol precursors and fatty acids. The macroscopic manifestation of these molecular alterations includes decreased high-density lipoprotein and increased very low-density lipoprotein and triglycerides that may translate into obesity and related metabolic disorders.

AB - Antipsychotics frequently cause obesity and related metabolic disorders that current psychopharmacological/endocrinological theories do not explain consistently. An integrative/alternative theory implies metabolic alterations happening at the cellular level. Many observations in vitro and in vivo, and pivotal observations in humans, point towards chemical properties of antipsychotics, independent of receptor binding characteristics. Being amphiphilic weak bases, antipsychotics can disrupt lysosomal function, affecting cholesterol trafficking; moreover, by chemical mimicry, antipsychotics can inhibit cholesterol biosynthesis. These two molecular adverse effects may trigger a cascade of transcriptional and biochemical events, ultimately reducing available cholesterol while increasing cholesterol precursors and fatty acids. The macroscopic manifestation of these molecular alterations includes decreased high-density lipoprotein and increased very low-density lipoprotein and triglycerides that may translate into obesity and related metabolic disorders.

KW - antipsychotic drugs

KW - cholesterol

KW - lysosomal trapping

KW - metabolism

KW - SREBP

KW - weight

UR - http://www.scopus.com/inward/record.url?scp=85060882387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060882387&partnerID=8YFLogxK

U2 - 10.1016/j.tem.2019.01.003

DO - 10.1016/j.tem.2019.01.003

M3 - Review article

AN - SCOPUS:85060882387

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

SN - 1043-2760

ER -